Top

Published in:

01-10-2012 | Case Report

Hemophagocytic syndrome in adult-onset Still’s disease (AOSD): A must for biologics?—Case report and brief review of the literature

Authors: Urs Bürgi, Adriana Mendez, Paul Hasler, Hans Dieter Hüllstrung

Published in: Rheumatology International | Issue 10/2012

Abstract

A case of adult-onset Still’s disease complicated by hemophagocytic lymphohistiocytosis is reported. Its management is being discussed on the background of the latest literature with special regard on the use of high-dose corticosteroids and immunosuppressive agents.

Still GF (1897) On a form of chronic joint disease in children. Med Chir Trans 80:47PubMed

Baywaters EG (1971) Stills disease in the adults. Ann Rheum Dis 30:121CrossRef

Yamaguchi M, Ohta A, Tsunematsu T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424PubMed

Arlet JB, Le TH, Marinho A et al (2006) Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis 65:1596PubMedCrossRef

Fukaya S, Yasuda S, Hashimoto T et al (2008) Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology 47:1686–1691PubMedCrossRef

Henter JI, Horne A, Aricó M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131PubMedCrossRef

Lambotte O, Khellaf M, Harmouche H et al (2006) Characteristics and long-term outcome of 15 episodes of systemic Lupus erythematodes-associated hemophagocytic syndrome. Medicine 85:169–182PubMedCrossRef

Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA (2005) Rapid response to Anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 52:1794–1803PubMedCrossRef

Lequerré T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67:302–308PubMedCrossRef

Title: Hemophagocytic syndrome in adult-onset Still’s disease (AOSD): A must for biologics?—Case report and brief review of the literature
Authors: Urs Bürgi
Adriana Mendez
Paul Hasler
Hans Dieter Hüllstrung
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 10/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1497-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hemophagocytic syndrome in adult-onset Still’s disease (AOSD): A must for biologics?—Case report and brief review of the literature

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2012

Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud’s phenomenon

Epidemiology of Paget’s disease of bone in the city of Recife, Brazil

Effectiveness of microwave diathermy on pain, functional capacity, muscle strength, quality of life, and depression in patients with subacromial impingement syndrome: a randomized placebo-controlled clinical study

Systemic sclerosis sine scleroderma associated with antiphospholipid syndrome

Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in reactive amyloidosis associated with rheumatoid arthritis

Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page